March 10, 2021 07:00 AM ESTUpdated March 12, 01:32 PM
R&D
Coronavirus

Eli Lil­ly tops up pos­i­tive PhI­II da­ta for its Covid-19 an­ti­body com­bo at ‘the op­ti­mal dose’

John Carroll

Editor & Founder

Eli Lil­ly has added an­oth­er brick in the wall of pos­i­tive da­ta as­sem­bled for its com­bo an­ti­body ther­a­py for Covid-19.

Its BLAZE-1 Phase III study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Can Bill An­der­son save Bay­er?

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

Kally­ope qui­et­ly re­ports Phase 2 obe­si­ty da­ta, be­gins mid-stage mi­graine tri­al

Verve is lat­est gene edit­ing com­pa­ny to suf­fer set­back, as Ver­tex walks away from pact

Start­up work­ing on oral an­ti­bod­ies shares ear­ly ul­cer­a­tive col­i­tis da­ta

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times